hotspot -WSS

hotspot

author：Wikipedia 2025-10-02 12:02:14 - browse：115

A psilocybin mushroom lays inside a clear capsule — Adobe

A single dose of psilocybin may have enduring benefits for people with major depressive disorder, according to a randomized clinical trial published Thursday in the Journal of the American Medical Association.

Several prior studies have suggested that psilocybin, the psychedelic compound produced by certain types of mushrooms, could be a promising way to treat major depression in people for whom antidepressants or counseling aren’t effective. But those studies mostly focused on short-term results, while the new JAMA study looked at psilocybin’s efficacy up to six weeks after the administration of a single dose of psilocybin.

“It’s exciting to see another study that’s coming out that is adding to the evidence base suggesting potential efficacy of psilocybin for depression, amongst other conditions,” said Greg Fonzo, an assistant professor and co-director for the Center for Psychedelic Research and Therapy at the University of Texas at Austin’s Dell Medical School, who was not involved in the study.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： Biogen says it will cut costs by $700 million, slash 1,000 jobs

hotspot

focus

WSS

The kidney, in all its complexity, is captured in a new atlas

Man who had jail sentence commuted by Trump arrested again

Man who had jail sentence commuted by Trump arrested again

What to watch for from Zogenix and Amicus clinical trials

Truvian presents data for its desktop blood

What causes rare myocarditis in young men after Covid vaccines?

hotspot

hotspot

hotspot

In Memoriam: Notable people who died in 2023

Dems pitch expanding Medicare power to negotiate drug prices

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

New lawsuit accuses health insurer Cigna of denying claims in bulk

Moonlake's readout produced a cash windfall. Risks remain

Roche’s Alnylam deal shows drug firms interested in heart drugs

DIEP, the 'gold standard' of breast reconstruction, is under threat

Will the FTC rein in IQVIA's health data empire?

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

New warning issued for rebooking air travel after delays, cancellations

focus

Device maker Teleflex to acquire urology company for $600M

Democrats decry new health bill for going easy on private equity

US economic growth accelerated in 2nd quarter, exceeding expectations and quieting recession fears

The kidney, in all its complexity, is captured in a new atlas

Medical experts are missing from AI regulatory conversations

No Labels group has 'steep climb,' but third party 'worth trying': Larry Hogan

hotspot

focus

knowledge

focus